STOCKS TELEGRAPH

Tag: PROG

  • Fiscal & Q4 2021 Results: Progenity Inc. (PROG) stock Plummets After Hours

    Fiscal & Q4 2021 Results: Progenity Inc. (PROG) stock Plummets After Hours

    On March 28, Progenity Inc. (PROG) declared its financial results for Q4 and fiscal 2021 after the market close. Consequently, the not-so-god results caused the stock to take a harsh hit in the after-hours as it tumbled further down.

    Source: Emerging Europe

    It seems investors were already unsure and fearful of what the earnings might hold, as the stock remained in the red during the regular session. After fluctuating between a low of $1.53 and a high of $1.75, PROG closed the session with a loss of 4.73%. At the close of the session, the stock had a value of $1.61 per share while 15.97 million shares were exchanged during the session. Following the earnings release, the stock plunged down to $1.19 per share in the after hours. Thus, PROG declined by a huge 26.09% at an after-hours volume of 5.19 million shares.

    The clinical molecular and specialized diagnostic tests provider, Progenity Inc. was founded in 2010. Currently, the company has a market capitalization of $276.74 million with its 163.75 million outstanding shares.

    PROG’s Latest Financial Results

    Q4 2021

    For Q4 2021, the company reported operating expenses of $20.6 million against $28.5 million for the year-ago quarter.

    Moreover, the company incurred a net loss of $92.9 million in the quarter against $75.5 million in the prior-year period. Hence, the net loss per share was $0.56 and $1.53 in Q4 fiscal 2021 and 2020 respectively.

    Additionally, the net loss from discontinued operations was $10.1 million or $0.06 per share in the quarter.

    Fiscal 2021

    For fiscal 2021, the company reported $60.6 million in revenues with $59.4 million from discontinued operations. This compares to $74.3 million with $74.2 million from discontinued operations in 2020.

    Furthermore, PROG had a net loss of $247.4 million or $2.57 per share in 2021, against $192.5 million or $7.00 per share in 2020.

    In addition, the net loss from discontinued operations was $68.9 million or $0.72 per share.

    PROG Company News

    On March 10, the company shared the progress of its Drug Delivery System (DDS) capsule performance study plan.

    In the first clinical device performance study of the DDS capsule, the company studied the safety, tolerability, and validation of its localization and delivery function. Following the ingestion of the capsule, the capsule localized and released saline solution with radioisotopes. The study demonstrated positive results in healthy volunteers. Therefore, PROG is now enrolling patients in the follow-on study in patients with active ulcerative colitis.

  • Progenity Inc. (PROG) stock Continues its Bullish Momentum Premarket on Patent Addition

    Progenity Inc. (PROG) is a molecular and specialized diagnostic tests provider, based in San Diego, CA. On January 25, the company announced the addition of another patent to its Single-Molecule Detection technology intellectual property. Following the announcement, the stock has been adding good value to its share price.

    In the previous trading session, PROG stock added a good 20.31% at its closing price of $1.54. At the last check, in the premarket on Wednesday, the stock had further increased by 9.74% at $1.69.

    Currently, the company has a market capitalization of $209.6 million with its 163.75 million shares outstanding. Furthermore, PROG stock stands at a year-to-date loss of 26.82%, while it lost 78.82% last year.

    PROG’s New Patent

    Progenity has further reinforced its patent portfolio with the addition of U.S. Patent No. 11,230,731 issued by USPTO. The patent titled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules” has been added to PROG’s single-molecule detection technology IP.

    The single-molecule detection platform warrants target analytes’ sequence-free counting. Therefore, the company believes it to have a potential impact on noninvasive prenatal testing and liquid biopsy. Additionally, this platform also warrants potentially cost-effective genomic tests with fewer turnaround times.

    According to the company’s General Manager of Diagnostics, Matthew Cooper, the company is evaluating its alternatives for accelerating its path to market.

    Upcoming Presentation

    On January 11, the company reported the acceptance of its oral presentation for the upcoming Belgian Week of Gastroenterology. The company will be presenting patient data on indicators of efficacy in gastrointestinal disorders treatment. Moreover, the 34th edition of the Belgian Week of Gastroenterology will take place from February 9 to 11, 2022.

    PROG’s Financial Analysis

    On November 10, the company declared its third-quarter financial results for 2021, which ended on September 30.

    In the third quarter of 2021, the company had revenues of $9.6 million, with $9.4 million resulting from discontinued operations.

    Further, PROG incurred a net loss of $43.7 million in Q3 of 2020, against $78.5 million in the previous quarter. Resultantly, the net loss per basic and diluted share was $0.46 and $1.23 in Q3 and Q2 of 2021, respectively.

    In addition, the company had a net loss of $6.9 from discontinued operations in Q3 of 2021, against $37.1 million in Q2 of 2021. Therefore, in 2021 the net loss from discontinued operations was $0.07/share and $0.58/share in Q3 and Q2, respectively.

  • Progenity, Inc. (PROG) stock gains, here’s what you should know

    Progenity, Inc. (PROG) stock gains, here’s what you should know

    Progenity, Inc. (PROG) stock gained value in pre-market after they announced the financial statement of their 3rd quarter on 10 November. Progenity, Inc. (PROG) stock saw 4.38% increase reaching to a value of $3.10 in premarket.  The volume of the stock traded was 111.36 Million.

    Milestones achieved in the 3rd quarter of the current financial year:

    • Inclusion of significant patents that will help protecting the therapeutic delivery of the company.
    • This year Progenity, Inc. (PROG) implemented cost reducing measure. These measures are expected to save $145 million annually.
    • Partnership with a large pharmaceutical company that will to evaluate OBDS that is currently under developing.

    Financial Highlights:

    • Revenue for the 3rd quarter was $9.6 million out of which $9.4 million was generated from the operations which were discontinued by the company for some reasons.
    • Expenses were reduced to $30.7 million as compared to the expenses of 2nd quarter which were $36.1 million.
    • Net loss for the 3rd quarter was $43.7 million. Net loss in the 2nd quarter was $78.5 million.
    • Progenity, Inc. (PROG) shares have lost 33.35 in value since the beginning of the year.

    Impact of financial statement announcement on the stock price:

    The Progenity, Inc. (PROG) announced its 3rd quarter financial statement on 10 November 2021. Before the announcement of its financial statements the estimated revision trends for Progenity, Inc. (PROG) were mixed. The impact of the proposed revised estimation as per the company’s just released financial statement. The stock is expected to be in line with the market in the near future.

    What next for the Progenity, Inc. (PROG) stock ?

    Although Progenity, Inc. (PROG) did not performed well in this year. Is this stock still worth investing? Well there is no absolute answer to this question but one thing that investors should look upon is that to keep track of its quarterly earnings. That is one variable for the estimation. The outlook of the Industry has also the huge impact on the share price of a company.

    Conclusion:

    Despite for its unstable trend in the market, the financial report of the Progenity, Inc. (PROG)reveals that the company is planning to expand its operations. Progenity, Inc. (PROG) have managed to half the loss as per the previous quarter, which shows that Progenity, Inc. (PROG) is practically implementing to reduce the expenses. They 4 new patents will help them improve and keep their technology up to date.

  • Progenity Inc. (PROG) Stock Skyrockets as Next Target of Reddit-Driven Meme Stock Phenomenon

    Progenity Inc. (PROG) Stock Skyrockets as Next Target of Reddit-Driven Meme Stock Phenomenon

    Progenity Inc. (PROG) stock prices soared by a massive 28.92% as of the market closing on June 11th, 2021, bringing the price per share up to USD$3.21 at the end of the trading day. Pre-market fluctuations saw the stock surge by another 12.77%, bringing it up to USD$3.62.

    Meme Stock Phenomenon

    The past several trading days have seen the stock market being dominated by the meme stock phenomenon that spurred the GME and AMC developments earlier in the year. In the absence of any significant news or developments, the recent surge in PROG stock prices is likely to be attributable to the coordinated pump by investors who are users of the popular social media platform, Reddit. With a relatively high percentage of shorted shares, at 6.7%, the company is a prime target for Reddit-driven retail investors.

    Private Placement

    Concurrent with the surge in stock price, PROG announced on June 10th, 2021 that it had entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds. The agreement will see the sale of units comprised of shares of common stock and warrants. The stocks are interchangeable with pre-funded warrants to purchase common stock and the warrants are for the purchase of common stock.

    Details of the Placement

    The private placement is expected to result in the generation of gross proceeds amounting to USD$40 million before the deduction of expenses related to the offering. As per the agreement, the closing of the placement will be followed by the issuance of units representing 16,194,332 shares of common stock (or pre-funded warrants. Warrants will also be issues concurrently, which will allow for the purchase of an aggregate of another 16,194,332 shares of common stock.

    Pricing of Placement

    Each unit issues by PROG will consist of one share of common stock, as well as one warrant to purchase one share of common stock. The price of each combined unit has been set at USD$2.47. Each warrant will have an exercise price of USD$2.84 per share with the option to be exercised at any time within 5 years of the issuance.

    Closing of the Placement

    The price per unit was partially determined by the average of the last five closing price of PROG’s common stock on the Nasdaq Global Market. Should the warrants be exercise for cash, the company will see the generation of additional gross proceeds of almost USD$46 million. The closing date of the placement is expected for June 14th, 2021, pending the satisfaction of customary closing conditions.

    Future Outlook for PROG

    Armed with a solid liquidity position from their private placement, as well as the fortuitous surge in value of their equity, PROG is poised to capitalize on the opportunities presented to it. The company is keen to continue its trajectory of success and usher in more organic growth over the long-term. Current and potential investors are hopeful that the management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.

  • Market Movers: What changed for these 37 stocks while you were sleeping

    Market Movers: What changed for these 37 stocks while you were sleeping

    Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will begin a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. Company’s 52-week ranged between $0.53 to $3.10. Analysts have a consensus price target of $7.75.
    SELLAS Life Sciences Group Inc. (SLS) stock plunged -24.18% to $13.39 in the pre-market trading. The most recent rating by Oppenheimer, on November 01, 2018, is an Outperform.
    Veru Inc. (VERU) tumbled over -11.89% at $5.26 in pre-market trading today. The firm recently declared that it has exclusively licensed phase 3 clinical stage targeted therapy for endocrine resistant metastatic breast cancer.
    Before the trading started on December 11, 2020, Professional Diversity Network Inc. (IPDN) is down -25.0% to reach $1.53. It has been trading in a 52-week range of $0.76 to $3.98.
    Neos Therapeutics Inc. (NEOS), a Drug Manufacturers – Specialty & Generic company, dropped about -16.36% at $0.6832 in pre-market trading Friday after announcing definitive merger agreement with Aytu BioScience, pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Callon Petroleum Company (CPE) is down more than -0.53% at $15.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 7.71% to $15.08 in the last trading session.
    C3.ai Inc. (AI) stock moved down -5.38 percent to $123.0 in the pre-market trading. The company lately declared the pricing of its initial public offering of 15,500,000 shares of its Class A common stock at a price of $42.00 per share.
    Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) shares are trading up 2.21% at $1.85 at the time of writing. Company’s 52-week ranged between $1.00 to $6.90. Analysts have a consensus price target of $14.
    Regulus Therapeutics Inc. (RGLS) stock plunged -9.92% to $1.09 in the pre-market trading. The healthcare company revealed closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is a Neutral.
    Range Resources Corporation (RRC) stock plunged -4.79% to $7.35 in the pre-market trading. The most recent rating by Stephens, on November 16, 2020, is an Overweight.
    Zedge Inc. (AMEX: ZDGE) shares are trading up 23.7% at $6.68 at the time of writing after reporting first fiscal quarter revenue growth of 85% and record overall quarterly financial results. Company’s 52-week ranged between $0.66 to $4.70. Analysts have a consensus price target of $3.
    Hennessy Capital Acquisition Corp. IV (HCAC), a Shell Companies company, dropped about -5.82% at $20.72 in pre-market trading Friday.
    Editas Medicine Inc. (EDIT) grew over 0.84% at $67.4 in pre-market trading today. The company recently publicized submission of IND application for EDIT-301 with the FDA.
    Greenwich LifeSciences Inc. (GLSI) is down more than -9.3% at $65.5 in pre-market hours Friday December 11, 2020 following the today’s announcement of poster presentation on its GP2 phase III clinical trial design for recurring breast cancer. The stock had jumped over 26.48% to $72.22 in the last trading session.
    Silver Spike Acquisition Corp. (SSPK) is down more than -2.78% at $14.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 37.27% to $14.40 in the last trading session.
    Biocept Inc. (BIOC) stock plunged -3.07% to $5.68 in the pre-market trading after declaring results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The most recent rating by Chardan Capital Markets, on November 14, 2017, is a Buy.
    W&T Offshore Inc. (NYSE: WTI) shares are trading down -6.02% at $2.5 at the time of writing following the firm provided an operational update regarding fourth quarter 2020 production. Company’s 52-week ranged between $1.07 to $6.10.
    Before the trading started on December 11, 2020, Platinum Group Metals Ltd. (PLG) is up 1.93% to reach $5.27. It has been trading in a 52-week range of $0.86 to $5.20.
    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -24.72% at $6.12 in pre-market trading Friday after the company and Neos Therapeutics declared definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Torchlight Energy Resources Inc. (TRCH) stock soared 13.78% to $0.7226 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.
    Before the trading started on December 11, 2020, Energy Fuels Inc. (UUUU) is up 1.64% to reach $3.1 following the announcement from the company that that its President and CEO Mark S. Chalmers will be presenting live at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 11:40 AM (EST). It has been trading in a 52-week range of $0.78 to $2.99.
    Ashford Hospitality Trust Inc. (NYSE: AHT) shares are trading up 8.04% at $4.3 at the time of writing. Company’s 52-week ranged between $1.27 to $29.44.
    ClearOne Inc. (CLRO) stock plunged -7.2% to $2.45 in the pre-market trading after declaring that it has appointed Chromasound PLC, based in Budapest, Hungary, as its newest distribution partner. The most recent rating by Singular Research, on August 16, 2018, is a Buy – long-term.
    ReWalk Robotics Ltd. (NASDAQ: RWLK) shares are trading up 3.7% at $1.4 at the time of writing after revealing a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury (SCIs) to apply for the procurement of a ReWalk 6.0 exoskeleton system. Company’s 52-week ranged between $0.41 to $2.71. Analysts have a consensus price target of $1.50.
    Progenity Inc. (PROG) grew over 9.32% at $4.34 in pre-market trading today. The firm recently reported closing of the convertible senior notes offering and partial exercise of the Initial purchaser’s option to purchase additional notes.
    Boxlight Corporation (BOXL) is down more than -7.69% at $1.8 in pre-market hours Friday December 11, 2020. The stock had jumped over 17.47% to $1.95 in the last trading session.
    Lemonade Inc. (LMND), a Insurance – Property & Casualty company, rose about 0.7% at $100.4 in pre-market trading Friday. The company recently declared that residents of France can now get renters insurance instantly, anytime, and from any device – as well as file claims and get paid in seconds through the Lemonade app.
    ObsEva SA (OBSV) lost over -2.54% at $2.3 in pre-market trading Friday December 11, 2020 after announcing topline 52-week PRIMROSE 1 and 76-week PRIMROSE 2 results of Yselty, in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids.
    Amplify Energy Corp. (AMPY) is down more than -27.33% at $1.09 in pre-market hours Friday December 11, 2020 following the commencement of an underwritten public offering of 8,548,485 shares of its common stock by certain of its stockholders which are affiliates of Fir Tree Capital Management L.P. The stock had jumped over 11.94% to $1.50 in the last trading session.
    Before the trading started on December 11, 2020, Hoth Therapeutics Inc. (HOTH) is up 0.54% to reach $1.85 after the firm revealed that it has received approval to commence phase 1b clinical trial of BioLexa for the treatment of Atopic Dermatitis in humans. It has been trading in a 52-week range of $1.60 to $7.25.
    RMG Acquisition Corp. (RMG) grew over 6.6% at $22.29 in pre-market trading today after declaring stockholder meeting Date of December 28, 2020.
    Marathon Patent Group Inc. (MARA) is down more than -10.34% at $4.68 in pre-market hours Friday December 11, 2020. The company recently stated that it has entered into a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners. The stock had jumped over 9.21% to $5.22 in the last trading session.
    Before the trading started on December 11, 2020, Inseego Corp. (INSG) is up 7.26% to reach $13.15. The firm today reported that the it is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. It has been trading in a 52-week range of $3.91 to $15.25.
    Entera Bio Ltd. (ENTX) tumbled over -7.56% at $1.1 in pre-market trading today after revealing FDA approval of IND application for EB613 – an oral human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.
    OncoCyte Corporation (OCX) stock moved up 3.23 percent to $2.24 in the pre-market trading. The firm recently reported that it will host a key opinion leader (KOL) call on the Company’s proprietary DetermaRx™ and DetermaIO™ molecular tests for cancer treatment selection on Tuesday, December 15, 2020 at 11:00am Eastern Time.
    ZK International Group Co. Ltd. (ZKIN) lost over -4.98% at $2.1 in pre-market trading Friday December 11, 2020 after declaring that it signed a letter of intent with Tuopeng Industrial, a prominent construction and real estate company.
    Before the trading started on December 11, 2020, Arbutus Biopharma Corporation (ABUS) is up 15.8% to reach $4.25. It has been trading in a 52-week range of $0.88 to $9.02 following the declaration of additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.